CG Oncology Inc. (CGON) vs Immunovant, Inc. (IMVT)
A side-by-side comparison of CG Oncology Inc. and Immunovant, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGON
CG Oncology Inc.
$66.96HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
IMVT
Immunovant, Inc.
$32.71HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — CGON vs IMVT
growth of $100 · dividends reinvested · last 3yCGON +84.9% (+22.7%/yr)IMVT -13.0% (-4.6%/yr)CGON compounded faster over this window
CGON IMVT
CGON vs IMVT: by the numbers
- •IMVT is the larger company ($6.75B vs $5.91B market cap).
- •Both run net losses; CGON's is the smaller (-3602.68% vs -7585.86% net margin).
Metrics side by side
Valuation
| Metric | CGON | IMVT |
|---|---|---|
| P/S ratio | 948.30 | 951.67 |
| P/B ratio | 5.74 | 9.18 |
Profitability
| Metric | CGON | IMVT |
|---|---|---|
| Gross margin | -15.02% | 0.00% |
| Operating margin | -4722.13% | 0.00% |
| Net margin | -3602.68% | -7585.86% |
| ROE | -21.80% | -73.19% |
| ROIC | -24.33% | -76.00% |
Growth (annualized)
| Metric | CGON | IMVT |
|---|---|---|
| Total return CAGR (5Y) | N/A | 29.93% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.